Review: Angiotensin converting enzyme inhibitors and angiotensin receptor blockers prevent atrial fibrillation. Commentary

Evidence-Based Medicine

Volumn 11, Issue 1, 2006, Pages 15-

  Karthikeyan, V J ^a   Lip, Gregory Y H ^a  

^a CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; CARDIOVERSION; CLINICAL TRIAL; DRUG MECHANISM; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; META ANALYSIS; PARALLEL DESIGN; RISK BENEFIT ANALYSIS; RISK REDUCTION; SHORT SURVEY; VASCULAR DISEASE;

EID: 32544444441     PISSN: 13565524     EISSN: None     Source Type: Journal    
DOI: 10.1136/ebm.11.1.15     Document Type: Short Survey

References (2)

1. Choudhury A, Varughese GI, Gip GY. Targeting the renin-angiotensin-aldosterone-system in atrial fibrillation: a shift from electrical to structural theraphy? Expert Opin Pharmacother 2005;6:2193-207.
2. L'Allier PL, Ducharme A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol 2004;44:159-64.